Summary
Introduction In Western countries, the number of frail elderly people with metastatic melanoma (MM) keeps increasing. Conventional chemotherapy frequently induces imbalance in frail physiological cases. We propose to treat these patients with oral metronomic cyclophosphamide. Patients and methods This retrospective study analyses the data of patients with unresectable MM who received 50 to 100 mg of cyclophosphamide a day, 3 weeks out of 4. Main evaluation criterion was safety. Secondary evaluation criteria were objective response rate and overall survival. Results Thirteen patients were included (median age: 80, 5 AJCC stage III and 8 AJCC stage IV). Clinical and biological safety were good, leading to long home staying and rare treatment discontinuations. Main toxicity observed was lymphopenia; no opportunist infection occurred. The control rate was 46%: one partial response and five stable diseases (median: 10 months). Survival after beginning of treatment ranged from 4 to 37 months (median: 8 months). Discussion Literature about MM in frail elderly is limited. Still, specific treatment is necessary. Cyclophosphamide in metronomic schema was well tolerated. The response rate was difficult to assess (small population) but several patients presented with long lasting stabilisation. The mechanisms of action of this treatment are original, associating antiangiogenic action and immunomodulation. Conclusion Cyclophosphamide in metronomic schema showed good safety results for this frail population. Oral treatment enabled patients to stay at home longer and limited hospitalisation time. A larger controlled study will be necessary to confirm these encouraging results in elderly with MM, a classical chemoresistant tumor.
Similar content being viewed by others
References
Chérié-Challine L, Halna J-M, Remontet L (2004) Situation épidémiologique du mélanome cutané en France et impact en termes de prévention. Bull Epidémiol Hebd 2:5–8
Nashan D, Müller M, Grabbe S, Wustlich S, Enk A (2007) Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine. J Eur Acad Dermatol Venereol 21:1305–1318
Sasse A, Sasse E, Clark L, Ulloa L, Clark O (2008) Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma (review). Cochrane Database Syst Rev 24:CD005413
Balch C, Murray D, Presant C, Bartolucci A (1984) Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma. Surgery 95:454–459
Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de Braud F, Viale G, Goldhirsch A (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13:73–80
Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M (2005) Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 16:1243–1252
Lord R, Nair S, Schache A, Spicer J, Somailhah N, Khoo V, Pandha H (2007) Low dose metronomic oral cyclophosphamide for hormone resistant prostatic cancer: a phase II study. J Urol 177:2136–2140
Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, Kerbel RS (2004) A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64:3994–4000
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood J, McMasters K, Mihm MF, Morton D, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, ATv O, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216
Homsi J, Kashani-Sabet M, Messina JL, Daud A (2005) Cutaneous melanoma: prognostic factors. Cancer Control 12:223–229
Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier A, Guizard A, Tretarre B, Launoy G, Colonna M, Danzon A, Molinie F, Troussard X, Bourdon-Raverdy N, Carli P, Jaffré A, Bessaguet C, Sauleau E, Schvartz C, Arveux P, Maynadié M, Grosclaude P, Estève J, Faivre J (2007) Survival of cancer patients in France: a population-based study from the association of the french cancer registries (FRANCIM). Eur J Cancer 43:149–160
Balducci L (2007) Aging, frailty and chemotherapy. Cancer Control 14:7–12
Extermann M (2007) Interaction between comorbidity and cancer. Cancer Control 14:13–22
Carriere I, Dupuy A, Lacroux A, Cristol J, Delcourt C, Pathologies Liées à l’Age Study Group (2008) Biomarkers of inflammation and malnutrition associated with early death in healthy elderly people. J Am Geriatr Soc 56:840–846
Satariano W, Ragland D (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104–110
Freyer G, Geay J, Touzet S, Provencal J, Weber B, Jacquin J, Ganem G, Tubiana-Mathieu N, Gisserot O, Pujade-Lauraine E (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16:1795–1800
Kumar A, Soares HP, Balducci L, Djulbegovic B (2007) Treatment tolerance and efficacy in geriatric oncology : a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol 25:1272–1276
Hutchins L, Unger J, Crowley J (1999) Underrepresentation of patients 65 years of age and older in cancer treatment trials. N Engl J Med 341:2061–2067
Gogas H, Kirkwood J, Sondak V (2007) Chemotherapy for metastatic melanoma: time for a change? Cancer 109:455–464
Cashin R, Lui P, Machado M, Hemels M, Corey-Lisle P, Einarson T (2008) Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life-studies. Value Health 11:259–271
Avril M-F, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Porta VG, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Larriba JLG, Scherrer A, Menu Y (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118–1125
Hanahan D, Weinberg R (2000) The hallmarks of cancer. Cell 100:57–70
Awwad M, North RJ (1988) Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65:87–92
Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886
Mahabeleshwar G, Byzoya T (2007) Angiogenesis in melanoma. Semin Oncol 34:555–565
Hellwig SM, Damen CA, Adrichem NP, Blijham GH, Groenewegen G, Griffioen AW (1997) Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors. Cancer Lett 120:203–211
Dirkx AEM, MGAo E, Castermans K, DWJvd S, Thijssen VLJL, Dings RPM, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JCA, Griffioen AW (2006) Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 20:621–630
Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G (1996) Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancy: role of angiogenic factors. Cancer Res 56:1111–1117
Conforti A, Ollila D, Kelley M, Gammon G, Morton D (1997) Update on active specific immunotherapy with melanoma vaccines. J Surg Oncol 66:55–64
Salem M, Kadima A, El-Naggar S, Rubinstein M, Chen Y, Gillanders W, Cole D (1997) Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 30:40–53
Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels J-PH, Bieler J, Emens L, Reilly R, Jaffee EM (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591–1602
Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E (2007) Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 13:644–653
Tarhini A, Agarwala S (2006) Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 19:19–25
Balducci L (2006) Management of cancer in the elderly. Oncology (Williston Park) 20:135–143
Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342–4346
Griffith K, Read E, Carrasquillo J, Carter C, Yang J, Fischer B, Aebersold P, Packard B, Yu M, Rosenberg S (1989) In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 81:1709–1717
Matar P, Rozados VR, Gervasoni SI, Scharovsky GO (2002) Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 50:588–596
Tatsumi T, Kierstead L, Ranieri E, Gesualdo L, Schena F, Finke J, Bukowski R, Mueller-Berghaus J, Kirkwood J, Kwok W, Storkus W (2002) Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196:619–628
Lutsiak C, Semnani RT, Pascalis RD, Kashmiri SVS, Scholm J, Sabzevari H (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862–2868
Ben-Efraim S (2001) Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. Curr Drug Targets 2:197–212
Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Cesne AL, Zitvogel L, Chauffert B (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641–648
Awwad M, North RJ (1989) Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 49:1649–1654
Author information
Authors and Affiliations
Corresponding author
Additional information
Estelle Borne and Eve Desmedt have equal contribution.
Laurent Mortier and Sophie Vercambre-Darras are Co-Senior authors.
Rights and permissions
About this article
Cite this article
Borne, E., Desmedt, E., Duhamel, A. et al. Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs 28, 684–689 (2010). https://doi.org/10.1007/s10637-009-9298-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-009-9298-5